Hans Van Hulle1, Vincent Vakaet2, Renée Bultijnck3, Pieter Deseyne4, Max Schoepen5, Annick Van Greveling6, Giselle Post7, Wilfried De Neve8, Chris Monten9, Yolande Lievens10, Liv Veldeman11. 1. Department of Human Structure and Repair, Ghent University, Belgium. Electronic address: Hans.VanHulle@Ugent.be. 2. Department of Human Structure and Repair, Ghent University, Belgium; Department of Radiation Oncology, Ghent University Hospital, Belgium. Electronic address: Vincent.Vakaet@Ugent.be. 3. Department of Human Structure and Repair, Ghent University, Belgium. Electronic address: Renee.Bultijnck@ugent.be. 4. Department of Human Structure and Repair, Ghent University, Belgium; Department of Radiation Oncology, Ghent University Hospital, Belgium. Electronic address: Pieter.Deseyne@Uzgent.be. 5. Department of Human Structure and Repair, Ghent University, Belgium; Department of Industrial Systems Engineering and Product Design, Kortrijk, Belgium. Electronic address: Max.Schoepen@Ugent.be. 6. Department of Radiation Oncology, Ghent University Hospital, Belgium. Electronic address: Annick.VanGreveling@Uzgent.be. 7. Department of Human Structure and Repair, Ghent University, Belgium. Electronic address: Giselle.Post@Ugent.be. 8. Department of Human Structure and Repair, Ghent University, Belgium; Department of Radiation Oncology, Ghent University Hospital, Belgium. Electronic address: Wilfried.DeNeve@Uzgent.be. 9. Department of Human Structure and Repair, Ghent University, Belgium; Department of Radiation Oncology, Ghent University Hospital, Belgium. Electronic address: Chris.Monten@Uzgent.be. 10. Department of Human Structure and Repair, Ghent University, Belgium; Department of Radiation Oncology, Ghent University Hospital, Belgium. Electronic address: Yolande.Lievens@Uzgent.be. 11. Department of Human Structure and Repair, Ghent University, Belgium; Department of Radiation Oncology, Ghent University Hospital, Belgium. Electronic address: Liv.Veldeman@Uzgent.be.
Abstract
INTRODUCTION: In breast cancer patients, duration of illness and treatment have a negative impact on the quality of life. The duration of radiotherapy can be shortened by reducing the number of treatment fractions. In this study, the impact of an accelerated breast irradiation schedule in 5 fractions over 10 to 12 days on health-related quality of life (HRQoL) was investigated and compared to a standard hypofractionation schedule of 15 fractions. METHODOLOGY: The study population was composed of 530 patients treated in 15 fractions and 196 patients treated in 5 fractions. Patients were included in different trials evaluating HRQoL. Radiotherapy-related items of the EORTC QLQ-C30 and BR23 and Breast-Q questionnaires were evaluated by comparing baseline scores to scores at 2-4 weeks and 1 year after radiotherapy. Clinically important improvements and deteriorations of HRQoL were compared between the 2 radiation schedules. RESULTS: Patients treated in 5 fractions show less deterioration of physical well-being 2-4 weeks after radiotherapy. One year after radiotherapy, the 5 fractions schedule results in more patients reporting a clinically important improvement in pain, arm and breast symptoms and future perspective. CONCLUSION: Radiotherapy in 5 fractions over 10-12 days results in more improvement and less deterioration of HRQoL than a 15 fractions schedule over 3 weeks.
INTRODUCTION: In breast cancerpatients, duration of illness and treatment have a negative impact on the quality of life. The duration of radiotherapy can be shortened by reducing the number of treatment fractions. In this study, the impact of an accelerated breast irradiation schedule in 5 fractions over 10 to 12 days on health-related quality of life (HRQoL) was investigated and compared to a standard hypofractionation schedule of 15 fractions. METHODOLOGY: The study population was composed of 530 patients treated in 15 fractions and 196 patients treated in 5 fractions. Patients were included in different trials evaluating HRQoL. Radiotherapy-related items of the EORTC QLQ-C30 and BR23 and Breast-Q questionnaires were evaluated by comparing baseline scores to scores at 2-4 weeks and 1 year after radiotherapy. Clinically important improvements and deteriorations of HRQoL were compared between the 2 radiation schedules. RESULTS:Patients treated in 5 fractions show less deterioration of physical well-being 2-4 weeks after radiotherapy. One year after radiotherapy, the 5 fractions schedule results in more patients reporting a clinically important improvement in pain, arm and breast symptoms and future perspective. CONCLUSION: Radiotherapy in 5 fractions over 10-12 days results in more improvement and less deterioration of HRQoL than a 15 fractions schedule over 3 weeks.
Authors: Jonatas Gomes Barbosa da Silva; Diogo Timóteo Costa; Iago Dillion Lima Cavalcanti; Mariane Cajubá de Britto Lira Nogueira; Diego Augusto Lopes Oliveira Journal: Can Oncol Nurs J Date: 2022-04-01
Authors: Jonatas Gomes Barbosa da Silva; Diogo Timóteo Costa; Iago Dillion Lima Cavalcanti; Mariane Cajubá de Britto Lira Nogueira; Diego Augusto Lopes Oliveira Journal: Can Oncol Nurs J Date: 2022-04-01
Authors: Hans Van Hulle; Vincent Vakaet; Giselle Post; Annick Van Greveling; Chris Monten; An Hendrix; Koen Van de Vijver; Jo Van Dorpe; Pieter De Visschere; Geert Braems; Katrien Vandecasteele; Hannelore Denys; Wilfried De Neve; Liv Veldeman Journal: Pilot Feasibility Stud Date: 2020-10-10
Authors: Andrew N Jordan; Christine Anning; Lindsay Wilkes; Claire Ball; Nicola Pamphilon; Christopher E Clark; Nicholas G Bellenger; Angela C Shore; Andrew S P Sharp; Jose M Valderas Journal: Health Qual Life Outcomes Date: 2022-03-04 Impact factor: 3.186